Výsledky vyhledávání - "Stephen A. Wring"

MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis

Autor: Andrej, Spec, John, Pullman, George R, Thompson, William G, Powderly, Ellis H, Tobin, Jose, Vazquez, Stephen A, Wring, David, Angulo, Silvia, Helou, Peter G, Pappas, Loren, Miller

Publikováno v: Journal of Antimicrobial Chemotherapy. 74:3056-3062

Objectives To evaluate the safety and efficacy of two dosing regimens of oral ibrexafungerp (formerly SCY-078), a novel orally bioavailable β-glucan synthase inhibitor, in subjects with invasive candidiasis versus the standard of care (SOC) and to i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1713217864d6b2789b340677be301e18
https://doi.org/10.1093/jac/dkz277

Zobrazit plný text záznamu

Clinical Pharmacokinetics and Drug-Drug Interaction Potential for Coadministered SCY-078, an Oral Fungicidal Glucan Synthase Inhibitor, and Tacrolimus

Autor: Michael S. Willett, Stephen A. Wring, Michele Hyman, David Angulo, Gail Murphy, George Atiee, Christy Corr

Publikováno v: Clinical Pharmacology in Drug Development. 8:60-69

SCY-078 is an orally bioavailable triterpenoid glucan synthase inhibitor in clinical development as an intravenous and oral treatment of fungal infections caused by Candida and Aspergillus species. This was a sequential, single-center, open-label pha

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c32f8b0b1983c1122e15cca798f0c048
https://doi.org/10.1002/cpdd.588

Zobrazit plný text záznamu

Lack of Impact by SCY-078, a First-in-Class Oral Fungicidal Glucan Synthase Inhibitor, on the Pharmacokinetics of Rosiglitazone, a Substrate for CYP450 2C8, Supports the Low Risk for Clinically Relevant Metabolic Drug-Drug Interactions

Autor: Christy Corr, David Angulo, Michele Hyman, George Atiee, Gail Murphy, Michael S. Willett, Stephen A. Wring

Publikováno v: Journal of Clinical Pharmacology

SCY‐078, the first in a new class of β 1,3‐glucan synthesis inhibitors, is being developed as an oral and intravenous antifungal treatment for Candida and Aspergillus species fungal infections. In vitro, studies indicated SCY‐078 is an inhibit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41fe896dcc61846a6276f4edbf7e5d9e
https://doi.org/10.1002/jcph.1146

Zobrazit plný text záznamu

Akademický článek

SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis.

Publikováno v: PLoS Neglected Tropical Diseases, Vol 5, Iss 6, p e1151 (2011)

BACKGROUND: Human African trypanosomiasis (HAT) is an important public health problem in sub-Saharan Africa, affecting hundreds of thousands of individuals. An urgent need exists for the discovery and development of new, safe, and effective drugs to

Externí odkaz: https://doaj.org/article/63cd3700496b42e79618890a16e02bc3

Zobrazit plný text záznamu

Safety, tolerability, pharmacokinetics and pharmacodynamics after repeated once or twice daily RVT-1201, a TPH inhibitor for treatment of PAH

Autor: Philip Evans, Stephen A. Wring, David Carpenter, Michelle Palacios, Katelyn Crizer, Julie Rurka, Laurence H Keller, Michele Snyder

Publikováno v: Pulmonary hypertension.

Background: Pulmonary arterial endothelial cell tryptophan hydroxylase (TPH) expression is upregulated in pulmonary arterial hypertension (PAH) leading to elevated serotonin that drives proliferation of pulmonary artery smooth muscle cells (PASMCs),

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::84bd4921f93fd0f0d66ffee75d55408b
https://doi.org/10.1183/13993003.congress-2019.pa4748

Zobrazit plný text záznamu

SCY-078, a Novel Fungicidal Agent, Demonstrates Distribution to Tissues Associated with Fungal Infections during Mass Balance Studies with Intravenous and Oral [ 14 C]SCY-078 in Albino and Pigmented Rats

Autor: David Angulo, Stephen A. Wring, Katyna Borroto-Esoda, Eric G. Solon

Publikováno v: Antimicrobial Agents and Chemotherapy. 63

SCY-078, a fungicidal β-1,3-glucan synthesis inhibitor administered as intravenous or oral [ 14 C]SCY-078 to rats, was distributed primarily into tissues associated with invasive fungal disease (kidney, lung, liver, spleen, bone marrow, muscle, vagi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::db1dc3469e1901573d047972552fe5c5
https://doi.org/10.1128/aac.02119-18

Zobrazit plný text záznamu

Topical Treatment for Cutaneous Leishmaniasis: Dermato-Pharmacokinetic Lead Optimization of Benzoxaboroles

Autor: Eric Gaukel, Seong Hee Park, Sara Schock, Ryan Randolph, Robert T. Jacobs, Stephen A. Wring, Deirdre Hauser, Jacob J. Plattner, Vanessa Yardley, Tejal Merchant, Katrien Van Bocxlaer, Simon L. Croft

Cutaneous leishmaniasis (CL) is caused by several species of the protozoan parasite Leishmania , affecting an estimated 10 million people worldwide. Previously reported strategies for the development of topical CL treatments have focused primarily on

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7444f6b703a0193aea85c3554afc0252

Zobrazit plný text záznamu

Species-Selective Pyrimidineamine Inhibitors of Trypanosoma brucei S-Adenosylmethionine Decarboxylase

Autor: Margaret A. Phillips, Zhe Chen, Michael Peel, Jef K. De Brabander, Stephen A. Wring, Oleg A. Volkov, Anthony J. Brockway

Publikováno v: Journal of medicinal chemistry. 61(3)

New therapeutic options are needed for treatment of human African trypanosomiasis (HAT) caused by protozoan parasite Trypanosoma brucei. S-Adenosylmethionine decarboxylase (AdoMetDC) is an essential enzyme in the polyamine pathway of T. brucei. Previ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa209db4826b9383a4a0fa0f197437df
https://pubmed.ncbi.nlm.nih.gov/29271204

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání